This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Vertex Announces Upcoming Presentations Of Data At North American Cystic Fibrosis Conference

Stocks in this article: VRTX

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that five abstracts from its cystic fibrosis (CF) research and development program will be presented at the 27 th Annual North American Cystic Fibrosis Conference (NACFC) in Salt Lake City, Utah, October 17-19, 2013. Data from a Phase 3 study of ivacaftor in non- G551D gating mutations will be presented as well as long-term safety and efficacy data for KALYDECO™ (ivacaftor) from the PERSIST open-label rollover study. In addition, Fred Van Goor, Ph.D., Head of Biology for Vertex's CF program, and David Rodman, M.D., Vice President of Clinical Development for Vertex's CF program, will participate in invited talks regarding their work to discover and develop medicines that target the underlying cause of CF.

The accepted abstracts are now available in the online edition of Pediatric Pulmonology: Supplement: The 27th Annual North American Cystic Fibrosis Conference, Salt Palace Convention Center, Salt Lake City, Utah, October 17-19, 2013: http://onlinelibrary.wiley.com/doi/10.1002/ppul.v48.S36/issuetoc.

Abstracts

All abstracts will be presented as part of Poster Session 1 on October 17, 11:50 a.m. - 1:50 p.m. MDT:

  • “Ivacaftor, a CFTR potentiator, in cystic fibrosis patients who have a non- G551D-CFTR gating mutation: Phase 3, Part 1 results.” Poster 241. Vertex also expects these data to be presented as part of Symposium III, “CFTR: Matching CFTR Mutations and Drugs,” on October 19, 10:30 a.m. - 12:20 p.m. MDT.
  • “Effect of ivacaftor in patients with cystic fibrosis and the G551D-CFTR mutation who have baseline FEV 1 >90% of predicted.” Poster 257.
  • Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the G551D-CFTR mutation: response through 144 weeks of treatment (96 weeks of PERSIST).” Poster 227.
  • “Effect of ivacaftor on circulating inflammatory indices in CF patients with the G551D-CFTR mutation.” Poster 259.
  • “Evaluation of the drug-drug interaction potential of ivacaftor on a combined oral contraceptive.” Poster 262.

Symposium Sessions

Two additional Vertex presentations will take place as part of invited talks during Symposium Sessions II and III:

  • “Matching Novel Therapies to CF-Causing Mutations in Cell-based Systems.” Fred Van Goor, Ph.D., will deliver an invited talk during Symposium Session III, “CFTR: Matching CFTR Mutations & Drugs,” on October 19 at 11:30 a.m. MDT.
  • “Lessons Learned From the Development of First Generation CFTR Modulators.” David Rodman, M.D., will deliver an invited talk during Symposium II, “NT/CFTR: Advances in the Therapeutic Pipeline for CFTR Repair (Combination),” on October 18 at 11:55 a.m. MDT.

About KALYDECOKALYDECO™ (ivacaftor) is the first medicine to treat the underlying cause of CF in people with the G551D mutation in the CFTR gene. Known as a CFTR potentiator, KALYDECO is an oral medicine that aims to help the CFTR protein function more normally once it reaches the cell surface, to help hydrate and clear mucus from the airways. KALYDECO (150mg, q12h) was first approved by the U.S. Food and Drug Administration in January 2012, by the European Medicines Agency in July 2012, by Health Canada in November 2012 and by the Therapeutic Goods Administration in Australia in July 2013 for use in people with CF ages 6 and older who have at least one copy of the G551D mutation in the CFTR gene.

Vertex retains worldwide rights to develop and commercialize KALYDECO.

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,856.72 +28.97 0.16%
S&P 500 2,069.80 -3.03 -0.15%
NASDAQ 4,800.3620 +13.0450 0.27%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs